Evidence map›Paper›PMID 37710306›Full record

ArticlePediatric blood & cancer2023

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.

Katherine Tarlock, Xiaowei Liu, Charles G Minard, Emasenyie A Isikwei, Joel M Reid, Terzah M Horton, Elizabeth Fox, Brenda J Weigel, Todd Cooper

Open access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Katherine TarlockDepartment of Pediatrics, Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-9717-2973
Xiaowei LiuChildren's Oncology Group, Monrovia, California, USA.
Charles G MinardInstitute of Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
Emasenyie A IsikweiDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Joel M ReidDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Terzah M HortonDepartment of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
Elizabeth FoxCancer Center, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Brenda J WeigelDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, University of Minnesota, Minneapolis, Minnesota, USA.
Todd CooperDepartment of Pediatrics, Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-1203-2371
Baylor College of Medicine · USMayo Clinic · USSeattle Children's Hospital · USChildren's Oncology Group · USSt. Jude Children's Research Hospital · USUniversity of Minnesota · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
PEP-CTN EHR to RAVE supplementUM1CA228823 · NCI · PUBLIC HEALTH INSTITUTE · PI Elizabeth Fox · 2018 to 2026
$39.6M
TRAINING GRANT IN CLINICAL PHARMACOLOGYT32GM008685 · NIGMS · MAYO CLINIC ROCHESTER · PI Liewei Wang · 1998 to 2026
$8.2M
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AMLR01CA164024 · NCI · BAYLOR COLLEGE OF MEDICINE · PI HORTON, TERZAH M · 2013 to 2017
$1.7M
NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA164024NCI NIH HHS UM1 CA228823NCI NIH HHS UM1CA228823NIGMS NIH HHS T32 GM008685NIGMS NIH HHS T32GM 08685
6 · The paper itself

Abstract

backgroundOutcomes for children with relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are poor, and new therapies are needed. Pevonedistat is an inhibitor of the NEDD-8 activating enzyme, a key regulator of the ubiquitin proteasome system that is responsible for protein turnover, with protein degradation regulating cell growth and survival. PROCEDURE: We evaluated the feasibility, toxicity, and pharmacokinetics (PK) of pevonedistat (20 mg/m

resultsOverall, three of 12 (25%) patients experienced DLTs. The day 1 mean ± SD (n = 12) C

conclusionsPevonedistat 20 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCyclopentanesLeukemia, Myeloid, AcutePyrimidinesAdolescentAdultAzacitidineChildChild, PreschoolChronic DiseaseCytarabineFeasibility StudiesHumansInfantMyelodysplastic SyndromesVidarabineAzacitidineCyclopentanesCytarabinefludarabinepevonedistatPyrimidinesVidarabineAMLpevonedistatrelapse

Identifiers

PMID37710306
PMCPMC10864008
OpenAlexW4386758376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.